Title: Vascular Endothelial Growth Factor (VEGF) in the Pathogenesis of Diabetic Nephropathy of Type 1 Diabetes Mellitus
Volume: 12
Issue: 1
Author(s): Maria Mironidou-Tzouveleki, Stergios Tsartsalis and Constantinos Tomos
Affiliation:
Keywords:
Nephropathy, pathogenesis, type 1 diabetes mellitus, VEGF, Diabetic nephropathy, Vascular endothelial growth factor, VEGFRs, hypertrophy, PlGF, angiogenesis, Rac, sFlt-1, glomerular endotheliosis, proteinuria, hypertension, glomerulosclerosis, glomerular filtration rate (GFR), Denys-Drash syndrome, nephritic syndrome, renal hypoxia, HIF, ERK, ROS, AGEs, albuminuria, microalbuminuria, CTAD, ELISA, Ranibizumab, Pegaptanib, Aflibercept, VEGF Trap-Eye, angiotensin converting enzyme (ACE)
Abstract: Diabetic nephropathy (DN) is a common complication of diabetes mellitus and is the primary cause of endstage renal disease in the Western World. Vascular endothelial growth factor (VEGF) is implicated in the pathogenesis of DN of type 1 diabetes mellitus. VEGF is the main angiogenic factor and a potent mitogen for endothelial cells. It is mainly produced in kidney by podocytes and exerts its biological activities by binding to its receptors (VEGFRs). Alternative splicing of a single VEGF gene produces various isoforms and two families with anti- and pro-angiogenic properties. In normal glomeruli, VEGF isoforms are in tight regulation and act in a paracrine and an autocrine manner preserving the integrity of glomerular filtration barrier. Many mediators in diabetic milieu induce the expression of VEGF and possibly the VEGFxxx isoform in animal models of type 1 diabetes, however, in human kidney with developed DN, VEGF expression seems to be lower or absent. Inhibition of VEGF in experimental DN ameliorates structural and functional changes and proposes possible therapeutic targets. Further studies are required before these treatments can be used in diabetic patients at early stages of DN.
